CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 9 No. 2 2
 

Sentinel Node Biopsy: Reasons for Failure

February 2, 2000

GREENVILLE, NC—Patient age and surgeon experience appear to play the biggest role in failure of sentinel lymph node biopsy for detection of breast cancer, according to a large multicenter clinical trial presented at the San Antonio Symposium.

In a multivariate analysis of potential factors associated with biopsy failure, only patient age of 50 years or greater and a procedural experience of 10 or fewer cases correlated significantly with failure, said Peter Ng, MD, of East Carolina University.

“Our data also suggest that medial tumor location correlates with a higher false-negative rate, though the correlation was not statistically significant in our series,” Dr. Ng said.

Dr. Ng reported findings from the first prospective, randomized, multicenter trial that used both radiolabeled sulfur(Drug information on sulfur) colloid and isosulfan blue dye to identify sentinel nodes. The study involved 485 patients and 41 surgeons. Three fourths of the patients had infiltrating ductal carcinoma, and 90% of the tumors were smaller than 5 cm. All sentinel node findings were confirmed by axillary node dissection.

“Participating surgeons were not required to have any prior experience with sentinel node biopsy outside of an initial training course,” Dr. Ng said. “No surgeon had participated in a learning trial of sentinel node biopsy prior to joining the study.”

The surgeons successfully identified the sentinel node in 420 of the 485 patients for an 87% success rate. In addition to the 65 patients with no sentinel node identified, there were 18 false-negative sentinel node biopsies (13%). A false-negative finding was defined as identification of a sentinel node that proved to be pathologically negative with a positive nonsentinel node identified by axillary dissection.

Correlation analysis of factors associated with biopsy success and failure included surgeon experience, probe type, primary tumor location, tumor size, method of tumor diagnosis (fine needle aspiration, core biopsy, previous lumpectomy, or previous biopsy), patient age, vascular lymphatic invasion, and dye injection interval.

Independent Predictors

Only patient age and surgeon experience proved to be significant independent predictors of sentinel node biopsy outcome. Mapping failure occurred in 5.1% of patients younger than 50, compared with 15.4% in patients 50 and older. Surgeons who performed more than 10 cases had a failure rate of 8.2%, compared with 17.9% for surgeons who had performed 10 or fewer cases.

Medial tumor location was a statistically significant predictor of biopsy success in a univariate analysis, but not in the multivariate analysis.

“On the basis of our results, we recommend that surgeons not abandon complete axillary node dissection without adequate sentinel node experience,” Dr. Ng concluded, “and that surgeons show discretion in applying this technique to older patients and those who have medial tumors.”

A Decrease in Lymphatics?

In answer to a question, Dr. Ng hypothesized that the failure rate in older women is due to anatomical changes that develop with age and fatty changes in the breast. “There’s probably a decrease in the lymphatics that in some way contributes to the increased failure rate,” he said.

When asked how many procedures are generally required to achieve an adequate success rate, Dr. Ng said he agreed with the consensus statement of the American College of Surgeons, which recommends 30 cases, with a success rate of greater than 85% and a false-negative rate of less than 5%.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy